CY1107715T1 - Διαγνωση και αγωγη του καρκινου του προστατη - Google Patents

Διαγνωση και αγωγη του καρκινου του προστατη

Info

Publication number
CY1107715T1
CY1107715T1 CY20071101073T CY071101073T CY1107715T1 CY 1107715 T1 CY1107715 T1 CY 1107715T1 CY 20071101073 T CY20071101073 T CY 20071101073T CY 071101073 T CY071101073 T CY 071101073T CY 1107715 T1 CY1107715 T1 CY 1107715T1
Authority
CY
Cyprus
Prior art keywords
hne
gated
voltage
nucleic acid
cancer
Prior art date
Application number
CY20071101073T
Other languages
English (en)
Inventor
Mustafa Bilgin Ali Djamgoz
Scott Paton Fraser
James Kenneth Joseph Diss
Original Assignee
Imperial Innovations Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Limited filed Critical Imperial Innovations Limited
Publication of CY1107715T1 publication Critical patent/CY1107715T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Μέθοδος διαγνώσεως του καρκίνου σε έναν ασθενή άνθρωπο περιλαμβάνουσα τα στάδια (i) της λήψεως ενός δείγματος περιέχοντος νουκλεϊνικό οξύ και/ή πρωτεΐνη από τον ασθενή· και (ii) του προσδιορισμού του αν το δείγμα περιέχει ένα επίπεδο νουκλεϊνικού οξέως ή πρωτεΐνης πυροδοτούμενου από τάση διαύλου Na+ hNe-Na σχετιζόμενου με τον καρκίνο. Μέθοδος αγωγής του καρκίνου περιλαμβάνουσα το στάδιο της χορηγήσεως σε έναν ασθενή ενός παράγοντα ο οποίος αποτρέπει επιλεκτικά τη λειτουργία του πυροδοτούμενου από τάση διαύλου Na+ hNe-Na. Γενετικό μόρφωμα περιλαμβάνον ένα νουκλεϊνικό οξύ το οποίο κωδικοποιεί ένα μόριο ικανό να αποτρέπει τη λειτουργία ενός πυροδοτούμενου από τάση διαύλου Na+ hNe-Na εκφραζόμενο σε ένα κύτταρο. Οι μέθοδοι και οι συνθέσεις είναι ιδιαίτερα κατάλληλες για τον καρκίνο του προστάτη.
CY20071101073T 2000-09-02 2007-08-09 Διαγνωση και αγωγη του καρκινου του προστατη CY1107715T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0021617.6A GB0021617D0 (en) 2000-09-02 2000-09-02 Diagnosis and treatment of cancer
EP01960979A EP1313882B1 (en) 2000-09-02 2001-09-03 Diagnosis and treatment of prostate cancer

Publications (1)

Publication Number Publication Date
CY1107715T1 true CY1107715T1 (el) 2013-04-18

Family

ID=9898761

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101073T CY1107715T1 (el) 2000-09-02 2007-08-09 Διαγνωση και αγωγη του καρκινου του προστατη

Country Status (10)

Country Link
US (2) US20060166194A1 (el)
EP (1) EP1313882B1 (el)
JP (1) JP2004507254A (el)
AT (1) ATE361993T1 (el)
AU (1) AU2001282364A1 (el)
CY (1) CY1107715T1 (el)
DE (1) DE60128368T2 (el)
ES (1) ES2288979T3 (el)
GB (1) GB0021617D0 (el)
WO (1) WO2002018637A2 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393657B2 (en) * 2001-04-12 2008-07-01 Imperial College Innovations Limited Diagnosis and treatment of cancer: I
AU2002251286A1 (en) * 2001-04-12 2002-10-28 Imperial College Innovations Limited Diagnosis and treatment of cancer:ii
US7670771B2 (en) * 2004-01-21 2010-03-02 University Of Utah Research Foundation Mutant sodium channel Nav1.7 nucleic acid methods
ES2537631T3 (es) * 2004-05-27 2015-06-10 The Regents Of The University Of Colorado Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
WO2007147074A2 (en) 2006-06-14 2007-12-21 Living Microsystems, Inc. Use of highly parallel snp genotyping for fetal diagnosis
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
WO2009067429A1 (en) * 2007-11-19 2009-05-28 Genentech, Inc. Compositions and methods for inhibiting tumor progression
GB0811360D0 (en) * 2008-06-20 2008-07-30 Imp Innovations Ltd Methods
LT2562268T (lt) 2008-09-20 2017-04-25 The Board Of Trustees Of The Leland Stanford Junior University Neinvazinis fetalinės aneuploidijos diagnozavimas sekvenavimu
CA2773983A1 (en) 2009-09-11 2011-03-17 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
CN103930437A (zh) 2011-03-16 2014-07-16 安姆根有限公司 Nav1.3和Nav1.7的强效及选择性抑制剂
US9636418B2 (en) 2013-03-12 2017-05-02 Amgen Inc. Potent and selective inhibitors of NAV1.7
EP2970408B1 (en) 2013-03-12 2018-01-10 Amgen Inc. Potent and selective inhibitors of nav1.7
AU2019291050A1 (en) * 2018-06-22 2020-12-24 F. Hoffmann-La Roche Ag Oligonucleotides for modulating SCN9A expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9703187A (es) * 1994-11-02 1998-02-28 Trophix Pharm Inc Canales de sodio especificos del sistema nervioso periferico, adn que codifica para mismos, cristalizacion, difraccion por rayos x, modelado molecular por computadora, diseño racional de farmacos seleccion de farmacos y metodos para la elaboracion y
US7312043B2 (en) * 2000-07-10 2007-12-25 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods

Also Published As

Publication number Publication date
US7759078B2 (en) 2010-07-20
WO2002018637A2 (en) 2002-03-07
US20060166194A1 (en) 2006-07-27
DE60128368D1 (de) 2007-06-21
AU2001282364A1 (en) 2002-03-13
DE60128368T2 (de) 2008-01-10
JP2004507254A (ja) 2004-03-11
EP1313882A2 (en) 2003-05-28
US20080145859A1 (en) 2008-06-19
ATE361993T1 (de) 2007-06-15
EP1313882B1 (en) 2007-05-09
ES2288979T3 (es) 2008-02-01
GB0021617D0 (en) 2000-10-18
WO2002018637A3 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
CY1107715T1 (el) Διαγνωση και αγωγη του καρκινου του προστατη
WO2002083945A3 (en) Diagnosis and treatment of cancer: i
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
BR9912007A (pt) Composições e métodos para terapia e diagnóstico de câncer de próstata
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
MXPA04000080A (es) Metodos de diagnostico de cancer en la vejiga, composiciones y metodos de rastreo de moduladores de cancer en la vejiga.
ATE377381T1 (de) Diffusionsbildgebung von gewebe
WO2004110345A3 (en) Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
ATE266723T1 (de) Lösung die chaotropische mittel enthält und verwendung dieser lösung in verfahren zur isolierung von dna, rna und proteinen
WO1999040197A3 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
ATE413881T1 (de) Verfahren und zubereitungen um resistenz gegen biologische oder chemische therapien zu überwinden
BR0109062A (pt) Inibidores de frutose-1,6-bisfosfatase de arila
DK2219031T3 (da) Anvendelse af leptin til behandling af human lipoatrofi og fremgangsmåde til bestemmelse af prædisposition for behandlinngen
DE60032784D1 (de) Markerproteine für prostatakrebs
Seebauer et al. Effects of cold physical plasma on oral lichen planus: an in vitro study (effects of CAP on OLP)
DE69942031D1 (de) In prostatakrebs exprimiertes gen
Fokias et al. Age determination through DNA methylation patterns in fingernails and toenails
CO5280032A1 (es) COMPOSICIONES RELACIONADAS CON ESTEAROIL-CoA DESATURASA HUMANA Y METODOS PARA TRATAR DESORDENES DE LA PIEL
NO985904D0 (no) TIE-2-reseptorligander (TIE-ligand-3, TIE-ligand-4), samt anvendelse derav
DE69920681D1 (de) Humaner k+ ionenkanal und therapeutische verwendungen davon
BR0312483A (pt) Anticorpos e seus usos
NO993653D0 (no) Fremgangsmåte for diagnose, prognose og behandling av glaukom og relaterte sykdommer
Tonami et al. Protein profile of pepsin-digested carious and sound human dentine
Wang et al. Identification of tumor angiogenesis-related genes by subtractive hybridization